FDA Approves First Gene Therapy for Severe Hemophilia A
FRIDAY, June 30, 2023 (HealthDay News) — The U.S. Food and Drug Administration on Thursday approved a costly single-dose gene therapy for patients with severe hemophilia A, a life-threatening hereditary bleeding disorder. The treatment is not cheap: Roctavian will cost $2.9 million for a single infusion, the Associated Press reported.Continue Reading